

JUN 20 2008

4081628

**Premarket Notification 510(k) Summary**  
**CoolTouch LC225/CoolTouch CoolLipo Nd:YAG Laser System**

This 510(K) Summary of safety and effectiveness for the CoolTouch LC225/CoolTouch CoolLipo Nd:YAG surgical laser system is submitted in accordance with the requirements of 21CFR 807.92.

Applicant:	New Star Lasers, Inc. dba CoolTouch, Inc.
Address:	9085 Foothills Boulevard Roseville, CA 95747
Contact Person:	Natalie R. Vollrath
Telephone:	(916) 677-1900
Fax:	(916) 677-1901
Preparation Date:	June 9, 2008
Device Trade Name:	CoolTouch LC225/CoolTouch CoolLipo Nd:YAG Surgical Laser
Common Name:	Nd:YAG Pulsed Surgical Laser
Classification Name:	Instrument, Surgical Powered, Laser 79-GEX
Legally Marketed Predicate Device:	CoolTouch LC215/CoolTouch CoolLipo Nd:YAG Laser System
Description of the CoolTouch LC225/CoolLipo Nd:YAG Surgical Laser:	The LC225/CoolLipo Nd:YAG Laser System produces laser emission at 1320nm. The laser consists of three interconnected sections: the cabinet which houses the power supply, the cooling system, the microcontroller and the laser, the fiber optics, and the handpiece or JouleTracker
Intended use of the CoolTouch LC225/ CoolLipo Nd:YAG Surgical Laser:	For use in dermatology for incision, excision, ablation and vaporization with hemostasis of soft tissue. For use in the treatment of fine lines and wrinkles. For treatment of back acne and atrophic acne scars. For treatment of reflux of the great and small saphenous veins associated with varicose veins and varicosities. For laser-assisted lipolysis.
Performance Data:	None
Conclusion:	Based on the evaluation of the risks and hazards and including various testing of the modifications, the CoolTouch LC225/CoolLipo Nd:YAG Surgical Laser System is substantially equivalent to the predicate device, the LC215.

Confidential

0014



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

**JUN 20 2008**

New Star Lasers, Inc.  
% Ms. Natalie R. Vollrath  
Quality Assurance/Regulatory Affairs  
Manager  
9085 Foothills Boulevard  
Roseville, California 95747

Re: K081628

Trade/Device Name: CoolTouch LC225/CoolTouch CoolLipo  
Regulation Number: 21 CFR 878.4810  
Regulation Name: Laser surgical instrument for use in general and plastic surgery  
and in dermatology  
Regulatory Class: II  
Product Code: GEX  
Dated: June 9, 2008  
Received: June 10, 2008

Dear Ms. Vollrath:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Mark N. Melkerson  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**510(k) Number** Pending

**Device Name** CoolTouch LC225/CoolTouch CoolLipo

**Indications for Use** The CoolTouch Model LC225/CoolTouch CoolLipo Nd:YAG Surgical Laser is indicated for the following:

- a) for use in dermatology for incision, excision, ablation and vaporization with hemostasis of soft tissue;
- b) for use in the treatment of fine lines and wrinkles;
- c) for treatment of back acne and atrophic acne scars;
- d) for treatment of reflux of the great and small saphenous veins associated with varicose veins and varicosities, and;
- e) for laser-assisted lipolysis.

Prescription Use   X    
(Part 21 CFR 801 Subpart D)

AND/OR

Over-the-Counter Use             
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)

*Neil R. Dyl for me*  
(Division Sign-Off)

**Division of General, Restorative,  
and Neurological Devices**

Page   1   of   1  

**510(k) Number**   K081628    
Confidential

0010